Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT04892277
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Registration Number
- NCT04882163
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04849715
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT04809766
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
DALY II USA/ MB-CART2019.1 for DLBCL
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)Transformed LymphomaCentral Nervous System LymphomaMantle Cell Lymphoma (MCL)Richter Transformation
- Interventions
- Biological: zamtocabtagene autoleucel (MB-CART2019.1)
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 248
- Registration Number
- NCT04792489
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed, Refractory, Multiple Myeloma
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 56
- Registration Number
- NCT04762745
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- Conditions
- Follicular Lymphoma (FL)Marginal Zone LymphomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04745832
- Locations
- 🇺🇸
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center, Springfield, Missouri, United States
🇺🇸Community Cancer Trials of Utah, Ogden, Utah, United States
🇨🇦Centre intégré universitaire de santé et de services sociaux de l'Estrie, Sherbrooke, Quebec, Canada
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Target Recruit Count
- 180
- Registration Number
- NCT04674813
- Locations
- 🇺🇸
Local Institution - 008, Baltimore, Maryland, United States
🇺🇸Local Institution - 009, Duarte, California, United States
🇺🇸Local Institution - 011, New York, New York, United States
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04673617
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸UF Health Shands Cancer Hospital, Gainesville, Florida, United States
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT04666038
- Locations
- 🇨🇦
Princess Margaret Hospital (Ontario), Toronto, Ontario, Canada
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇨🇳Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.